Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04787341
Title PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE)
Acronym PARERE
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Gruppo Oncologico del Nord-Ovest
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Facility Status City State Zip Country Details
U.O. Oncologia 2 Universitaria RECRUITING Pisa PI 56126 Italy Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field